CALIWAY BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 413 TWD | -1.08% |
|
+9.55% | +115.95% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7,528 | 26,600 |
| Enterprise Value (EV) 1 | 6,446 | 22,909 |
| P/E ratio | -25.1 x | -48.5 x |
| Yield | - | - |
| Capitalization / Revenue | 587 x | 683 x |
| EV / Revenue | 503 x | 588 x |
| EV / EBITDA | -21.3 x | -46.4 x |
| EV / FCF | -37,680,260 x | -85,994,424 x |
| FCF Yield | -0% | -0% |
| Price to Book | 6.48 x | 7.12 x |
| Nbr of stocks (in thousands) | 122,910 | 139,084 |
| Reference price 2 | 61.25 | 191.2 |
| Announcement Date | 4/21/23 | 3/4/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 18.65 | 10.35 | 12.34 | 12.82 | 38.93 |
| EBITDA 1 | -106.7 | -76.72 | -161.4 | -302.4 | -493.7 |
| EBIT 1 | -122.1 | -87.89 | -177.6 | -319.6 | -513.5 |
| Operating Margin | -654.87% | -849.16% | -1,439.72% | -2,493.17% | -1,318.88% |
| Earnings before Tax (EBT) 1 | -121.8 | -98.4 | -224.3 | -286.2 | -488.5 |
| Net income 1 | -121.8 | -98.49 | -224.3 | -286.2 | -488.5 |
| Net margin | -653.27% | -951.56% | -1,817.76% | -2,232.1% | -1,254.64% |
| EPS 2 | -1.743 | -0.9247 | -1.707 | -2.443 | -3.943 |
| Free Cash Flow | - | - | -29.73 | -171.1 | -266.4 |
| FCF margin | - | - | -240.91% | -1,334.34% | -684.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/10/22 | 9/23/22 | 9/23/22 | 4/21/23 | 3/4/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 134 | 42.4 | - | - | - |
| Net Cash position 1 | - | - | 547 | 1,083 | 3,691 |
| Leverage (Debt/EBITDA) | -1.254 x | -0.5527 x | - | - | - |
| Free Cash Flow | - | - | -29.7 | -171 | -266 |
| ROE (net income / shareholders' equity) | - | - | -64.9% | -31.6% | -19.9% |
| ROA (Net income/ Total Assets) | - | - | -23.5% | -20.5% | -12.7% |
| Assets 1 | - | - | 953.8 | 1,394 | 3,850 |
| Book Value Per Share 2 | -0.1300 | 0.4400 | 6.020 | 9.460 | 26.90 |
| Cash Flow per Share 2 | 0.3100 | 0.8300 | 5.450 | 5.320 | 24.60 |
| Capex | - | 2.31 | 14.9 | 14.2 | 8.6 |
| Capex / Sales | - | 22.29% | 120.79% | 110.48% | 22.09% |
| Announcement Date | 11/10/22 | 9/23/22 | 9/23/22 | 4/21/23 | 3/4/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +115.95% | 1.79B | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 6919 Stock
- Financials Caliway Biopharmaceuticals Co., Ltd.
